Your browser doesn't support javascript.
loading
Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms, Johannes C; Vallabhaneni, Sreeram; Mills, Caitlin E; Yapp, Clarence; Chen, Jia-Yun; Morelli, Eugenio; Waszyk, Patricia; Kumar, Sushil; Deming, Derrick; Moret, Nienke; Rodriguez, Steven; Subramanian, Kartik; Rogava, Meri; Cartwright, Adam N R; Luoma, Adrienne; Mei, Shaolin; Brinker, Titus J; Miller, David M; Spektor, Alexander; Schadendorf, Dirk; Riggi, Nicolo; Wucherpfennig, Kai W; Sorger, Peter K; Izar, Benjamin.
Afiliación
  • Melms JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vallabhaneni S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mills CE; Columbia University Medical Center, Division of Hematology and Oncology, New York, New York.
  • Yapp C; Columbia Center for Translational Immunology, New York, New York.
  • Chen JY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Morelli E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Waszyk P; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Kumar S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Deming D; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Moret N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rodriguez S; Experimental Pathology Service, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Subramanian K; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rogava M; Department of Immunology, Harvard Medical School, Boston, Massachusetts.
  • Cartwright ANR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Luoma A; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Mei S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Brinker TJ; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Miller DM; Columbia University Medical Center, Division of Hematology and Oncology, New York, New York.
  • Spektor A; Columbia Center for Translational Immunology, New York, New York.
  • Schadendorf D; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Riggi N; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sorger PK; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Izar B; National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Res ; 80(4): 798-810, 2020 02 15.
Article en En | MEDLINE | ID: mdl-31882401

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Azepinas / Proteínas Serina-Treonina Quinasas / Resistencia a Antineoplásicos / Péptidos y Proteínas de Señalización Intracelular / Indoles / Melanoma Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Azepinas / Proteínas Serina-Treonina Quinasas / Resistencia a Antineoplásicos / Péptidos y Proteínas de Señalización Intracelular / Indoles / Melanoma Límite: Animals / Female / Humans Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos